Vixotrigine clinical trials
Also written BIIB074 and CNV1014802.
How each study uses vixotrigine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2016 (6)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 0
Often tested with
Tested in the same studies.
Valproic Acid (1) · BIIB-095 (1)
Studies
Open first, then newest update. How each study uses vixotrigine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 20
- 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaWithdrawnPhase 3BiogenNCT03070132Written as BIIB074How we know
- 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaWithdrawnPhase 3BiogenNCT03637387Written as BIIB074How we know
- Efficacy and Safety Study of BIIB074 in Participants With Small Fiber NeuropathyTerminatedPhase 2BiogenNCT03339336Written as BIIB074How we know
- Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic PolyneuropathyWithdrawnPhase 1BiogenNCT04106050Written as BIIB074How we know
- Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074TerminatedPhase 2BiogenNCT02957617Written as BIIB074How we know
- A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal NeuralgiaCompletedPhase 2BiogenNCT01540630Written as CNV1014802How we know
- A Drug Interaction Study of BIIB074 and an Oral Contraceptive RegimenCompletedPhase 1BiogenNCT03324685Written as BIIB074How we know
- Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral RadiculopathyCompletedPhase 2BiogenNCT02935608Written as BIIB074How we know
- Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074CompletedPhase 1BiogenNCT03385525Written as BIIB074How we know
- A Phase 2a Study of BIIB074 in the Treatment of ErythromelalgiaCompletedPhase 2BiogenNCT02917187Written as BIIB074How we know
- Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.CompletedPhase 1BiogenNCT00908154Written as GSK1014802How we know
- Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy SubjectsTerminatedPhase 1BiogenNCT00964288Written as GSK1014802 low doseHow we know
- Study to Investigate the Effect of GSK1014802 on Ambulatory Blood PressureCompletedPhase 1BiogenNCT00955396Written as GSK1014802How we know
- Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy SubjectsCompletedPhase 1BiogenNCT02551497Written as CNV1014802How we know
- Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral RadiculopathyCompletedPhase 2BiogenNCT01561027Written as CNV1014802How we know
- PK & Tolerability of CNV1014802 in Young and Elderly Healthy VolunteersCompletedPhase 1BiogenNCT02359344Written as CNV1014802How we know
- PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian ParticipantsCompletedPhase 1BiogenNCT02831517Written as BIIB074How we know
- New Formulation and Food Effect Study of BIIB074CompletedPhase 1BiogenNCT02951221Written as BIIB074 Treatment AHow we know
- Absorption, Metabolism, and Excretion Study of BIIB074CompletedPhase 1BiogenNCT02751905Written as BIIB074How we know
- Effect of Itraconazole on the Pharmacokinetics of BIIB074CompletedPhase 1BiogenNCT02698267Written as BIIB074How we know
Given beside what is tested · 1 — vixotrigine is usual care or a partner of the new treatment
Codes
What other systems call vixotrigine · ClinicalTrials.gg INT000081
- MeSH (NLM) C000592131vixotrigineOne source NLM
- UNII (FDA) QQS4J85K6YVIXOTRIGINEConfirmed FDA, NLM, Wikidata
- Wikidata Q18386159vixotrigineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152899VixotrigineOne source FDA
- DrugBank DB11706One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592131 | vixotrigine | One source NLM |
| UNII (FDA) | QQS4J85K6Y | VIXOTRIGINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18386159 | vixotrigine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152899 | Vixotrigine | One source FDA |
| DrugBank | DB11706 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.